| 1 | 2021-11-03 | NanoAlchemie | US Non-Provisional Filed | “nanotechnology that creates stable, safe nano-dimensional structures that can be used to rapidly and precisely deliver psychedelic drugs, psilocybin, and medicinal mushroom extracts through the skin, through the gums in the mouth, through the gastrointestinal tract, and rapidly to the brain through the olfactory and trigeminal nerves in the nasal cavity”; psilocin in “nanostructures that can rapidly be absorbed directly through mucous membranes” |
| 2 | 2021-09-22 | Mydecine | US Non-Provisional and PCT Applications Filed | “final patent application with the [USPTO] and [WIPO] for one of its lead drug candidates, MYCO-003, which is being developed to offer enhanced treatment of anxiety and post-traumatic stress disorder (PTSD)” (MYCO-003 “is a psilocybin-based formula with reduced anxiety potential, with the aim of removing the possibility of “bad trips,” even with severely ill patients”) |
| 3 | 2021-09-10 | Lennham Pharmaceuticals | “New Patent Family” Announced | “methods of using psilocybin and psilocin in select patient populations, and may be broadly applicable to the approved use of any psilocybin-based products, including those containing naturally-derived or synthetic psilocybin as well as derivatives and analogs of psilocybin such as deuterated psilocybin” |
| 4 | 2021-09-03 | Blue Sun Mycology Group | US Patent Applications Filed and Announced | “method of sexual hybridization that can be performed in fewer steps and overcomes barriers set by species or genus”; “methods of creating novel interspecific or intergeneric psychoactive species of fungi, plants, and a combination of fungi and plant”; “method of combining foreign substances, molecules, and compounds into the already existing compounds found in fungi, thus creating new naturally created novel compounds” |
| 5 | 2021-08-17 | Cybin | US Non-Provisional Application Filed | “claims to compositions and methods to support certain elements of the company’s pre-clinical and research programs”; previously identified as covering “a library of psychedelic derivative drug development candidates” |
| 6 | 2021-08-16 | PsyBio | US Provisional Application Filed | Application “entitled Methods for the Production of a Methylated Tryptamines and Intermediates or Side Products, adding additional methylated tryptamines including compounds such as N,N-Dimethyltryptamine (“DMT”) and associated analogs for development of potential treatments for a variety of human health conditions” |
| 7 | 2021-08-03 | Mindset Pharma | PCT Application Filed | “ground-breaking process to synthesize psilocybin and psilocin [that] enables faster psilocin and psilocybin synthesis compared to many of the established methodologies used today and has advantages over current processes that include: lower cost, milder reaction conditions, more convenient operations, easily obtained commercially available raw materials, suitability for multi-kilogram scale manufacturing, and lower environmental impact” |
| 8 | 2021-07-29 | Nova Mentis | US Provisional Application Filed | “proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin” with “ability to produce these three psychedelically active tryptamine derivatives in greater than 98 per cent purity” |
| 9 | 2021-07-13 | PsyBio | US Provisional Application Filed | Application “entitled Psilocybin and Norbaeocystin Compositions and Methods of Treatment”; “contains 67 new inventive claims and further demonstrates the Company’s vision to build a strong intellectual property portfolio protecting numerous novel psychedelic drug candidates being developed for clinical trial evaluations” |
| 10 | 2021-07-07 | MYND Life Sciences | US Provisional Applications Announced | “MYND has expanded its IP holdings with four separate patent applications, including: A diagnostic biomarker with the potential to diagnose and monitor MDD and other diseases. Modulation of key pathways in the treatment of MDD utilizing Psilocybin analogs. Methods for regressing or delaying Alzheimer’s disease and related forms of dementia. Modulation of the key pathways in the in the treatment of inflammatory diseases utilizing Psilocybin analogs.” |
| 11 | 2021-06-24 | Numinus Bioscience | US Provisional Application Filed | A “sustainable, reproducible and easily scalable process will be used to rapidly generate therapeutic products from psychoactive fungi species that contain psilocybin, other psychoactive compounds and a range of additional beneficial compounds, some of which Numinus researchers characterized for the first time in psychedelic fungi. The resulting psychedelic products are intended to be delivered in micro or macro dosages to help treat mental health disorders.” |
| 12 | 2021-06-10 | MYND Life Sciences | US Provisional Application Filed | “targets regulation of inflammation and immune responses by modulating the Human Mycogene by turning a pro-inflammatory state into an anti-inflammatory state”; treating a “wide variety of neuropsychiatric disorders, including but not limited to” MDD, schizophrenia, anxiety, bipolar disorder, OCD, and PTSD, “among others”; “wide variety of molecules including psychedelics such as all analogs of psilocybin, LSD, mescaline and DMT” |
| 13 | 2021-05-26 | Cybin | PCT Application Filed | “The PCT claims a library of psychedelic derivative drug development candidates.” |
| 14 | 2021-05-20 | Cybin | US Provisional Application Filed | “novel compositions which are expected to have improved pharmacokinetic profiles while retaining key efficacy measures of the original molecules and discloses innovative methods of deploying the novel compositions with faster therapeutic onset of Cybin’s psychedelic tryptamine, while reducing psychedelic side effects and decreasing duration of the therapeutic effect thereof” |
| 15 | 2021-05-05 | Red Light Holland | US Provisional Application Filed | “Customized microdosing kits” with “personalized dosing amounts and protocols that are based on collected biometric and movement data, and correlated with the qualities and characteristics of Red Light Holland’s natural products” |
| 16 | 2021-04-29 | BetterLife Pharma | US Provisional Application Filed | “novel implantable subcutaneous product and its use in the prevention of psychedelic drug diversion”: “One major overlooked issue is the possibility of the patient consuming a full psychedelic dose of psilocybin or LSD as opposed to the prescribed microdose or resale of the drugs to someone other than the patient. BetterLife’s invention has solved this problem by use of an implant administered by in-office procedure performed by a physician.” |
| 17 | 2021-04-22 | Revive Therapeutics | US Provisional Application Filed | “At a high level, the provisional patent application describes tannin-chitosan composite OTF [oral thin-film] incorporating active pharmaceutical ingredients, such as psilocybin.” |
| 18 | 2021-03-18 | Allied Corp. | US Provisional Application Filed | “This provisional patent contemplates the full scope treatment of general depression and anxiety with a proprietary Rx prescription medication followed by a daily prophylactic dose of proprietary medicinal compositions. This includes a proprietary dosing and therapeutic regimen of psilocybin, additional functional mushrooms and cannabinoid therapeutics.” |
| 19 | 2021-03-11 | Aion Therapeutic | US Provisional Applications Filed (4) | “The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations.” |
| 20 | 2021-03-02 | NeonMind | US Provisional Applications Filed (4) | “The provisional patent applications include data derived from NeonMind’s initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind’s proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time.” |
| 21 | 2021-02-05 | Mindset Pharma | US Non-Provisional & PCT Applications Filed (3) | “applications cover a comprehensive range of novel diverse proprietary compounds designed to deliver similar therapeutic benefits to psilocybin with a lower overall metabolic liability and predictable duration of action, along with their related processing methods, potential compositions, and therapeutic uses”; “claim priority dates of the Company’s previously filed USPTO provisional applications, which were filed on February 4, 2020” |
| 22 | 2021-01-06 | Mydecine | US Provisional Applications Filed (7) | “the developing patent portfolio from Mydecine is targeted at addressing the known shortcomings of psilocybin for medical uses and includes novel drug design and delivery mechanisms, precise doseable formulations and new technologies for improved use of psilocybin in a medical context” |
| 23 | 2020-12-15 | Revive Therapeutics (acquired from PharmaTher) | US Provisional Application Filed | “Psilocybin Pharmaceutical Combination Therapies” for “novel combinations of certain FDA approved drugs with psilocybin as a potential therapeutic option to reduce the side effects and improve the effectiveness of psilocybin to treat neurological disorders” |
| 24 | 2020-12-04 | Lophora | US Provisional Application | “new chemical entity which has a different molecular scaffold from psilocybin but has the same ability to trigger biological responses via the serotonin 2A receptor with the difference being that [it] is selective… whereas psilocybin is a broad agonist that affects multiple receptors, this molecule … primarily activates the serotonin 2A receptor… theoretically we’ve got a molecule which is safer because we can specifically target 2A without touching 2B” |
| 25 | 2020-11-16 | Revive Therapeutics (acquired from PharmaTher) | US Provisional Application Filed | “potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™, the Company’s proprietary psychedelic drug repurposing artificial intelligence platform. The patent application, entitled “Use of Psilocybin in the Treatment of Cancers”, outlines psilocybin’s use of significant unmet medical needs for Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia” |
| 26 | 2020-11-12 | Silo Pharma | US Provisional Applications Filed (3) | “central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin” |
| 27 | 2020-11-05 | Richard Clark Kaufman | US Provisional Application Filed | “Compositions and methods for extraction, isolation, separation, stabilization and manufacturing stable dosage forms and nano-drug delivery systems of psilocin, psilocybin, psychedelic drugs, and medicinal mushrooms”; “protects fast-acting, stable dosage forms of Psilocin and psychedelic drugs in nano-structures taken by intranasal, intraoral, and transdermal methods” |
| 28 | 2020-10-20 | Allied Corp. | US Provisional Application Filed | “novel combination of psilocybin and proprietary mushroom formulation, as well as a novel treatment regimen targeting Post Traumatic Stress (PTSD), Depression and General Anxiety”; “novel micro-dose ratios of several medical mushroom compounds combined with additional natural health molecules” |
| 29 | 2020-10-07 | Mydecine/NeuroPharm | US Provisional Application Filed | “psychedelic therapy enhancer,” for treatment of psychiatric disorders, including enhancements for PTSD, “that reduces the enzymatic breakdown of psilocin, the active ingredient in psilocybin that causes psychedelic effects,” and “may result in an enhanced psychedelic experience in the treatment of PTSD, whether by extended in time, intensity, intensity per dose, or a combination thereof” |
| 30 | 2020-09-29 | Field Trip | US Provisional Application | “a novel psychedelic molecule derived from the chemical structures of known psychedelic substances. FT-104 is designed to provide unique and useful pharmacological features to make a commercially viable alternative to naturally derived substances such as psilocybin, DMT and LSD” |
| 31 | 2020-09-21 | Flourish Mushroom Labs | US Provisional Application Filed | “methods of using serotonin agonists, in particular, psychedelic mushroom actives, for weight loss”; ” use of microdose administration of psilocin/psilocybin to have the additional weight loss effect of increasing metabolism which, combined with a decrease in food cravings or compulsive overeating, or altering food choices to less calorie dense foods, could result in substantial and beneficial weight loss” |
| 32 | 2020-09-18 | PsyBio | PCT Application Filed | “methods for the production of psilocybin and intermediates and side products”; modular biosynthetic production platform for in vivo production of psilocybin in E. coli |
| 33 | 2020-09-14 | Lobe Sciences | US Provisional Applications (3) | administration to an individual a psilocybin-derived agent and/or N-acetylcysteine via nasal delivery system, in combination with programmed virtual and augmented reality (VR, AR) simulations; aims to alleviate unwanted and emotions linked with PTSD or mTBI with PTSD; multiple VR devices can be used for group therapy sessions; VR device can be controlled remotely |
| 34 | 2020-09-03 | Aion Therapeutic | US Provisional Applications Filed (5) | “new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms (edible and psychedelic), and other natural plants known for their medicinal properties”; “formulation claims directed to methods of treating numerous conditions including cancer, psychiatric disorders, addiction (opioid and alcohol), viral diseases, obesity, and inflammatory disorders” |
| 35 | 2020-08-20 | Psilera Bioscience | US Provisional Application Filed | “new chemical entities and delivery methods relating to psychedelics” |
| 36 | 2020-07-27 | Mindset Pharma | US Provisional Application Filed | “groundbreaking process to synthesize psilocybin and psilocin” [filed as PCT application and announced on 8/3/21] |
| 37 | 2020-07-09 | MagicMed Industries | US Provisional Application Filed | “composition of matter, drug formulation and process of preparation claims for novel psilocybin derivatives”; “anticipated to be the first in a series of applications that together will protect the Company’s broad portfolio of novel psilocybin molecular derivatives, the Psybrary™” |
| 38 | 2020-06-04 | NeonMind | US Provisional Application Filed | “therapeutic administration of psilocybin or psilocin (or analogs thereof) combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues” |
| 39 | 2020-05-26 | Frontier Neurochem | US Provisional Application Filed | “novel proprietary tryptamine compounds and methods of use thereof” |
| 40 | 2020-04-29 | Revive Therapeutics | US Provisional Applications | “methods of production of psilocybin-based formulations, including sublingual sprays, effervescent tablets, hard-shell capsules, sublingual and transmucosal delivery systems (i.e. gum drops, oral strips, dosing pens)”; “Psilocybin extraction and crystallization methodologies” |
| 41 | 2020-04-04 | Orthogonal Thinker | US Provisional Application Filed | “improved version of psilocin” named “Psilly”; “proprietary formula that uses natural, rather than biosynthetic, alkaloids” |
| 42 | 2020-03-27 | Champignon Brands | US Provisional Applications (4) | “combination of psilocybin and cannabidiol in treating mTBI with PTSD or standalone PTSD”; “novel delivery systems”; treatments for PTSD and OCD that are “enhanced by timely measured dosages of psilocybin and cannabidiol” |
| 43 | 2019-12-04 | CB Therapeutics | US Provisional Application Filed | “biosynthesis of psilocybin, psilocin and related tryptamine-based compounds typically found in plants and fungi” [published as US20210147888A1 on March 20, 2021] |